Search

Your search keyword '"Fanton, Annlyse"' showing total 15 results
Start Over Author "Fanton, Annlyse" Language english
15 results on '"Fanton, Annlyse"'

1. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Author

Kanaan, Reem, Carlier, Nicolas, Honoré, Isabelle, Chedevergne, Frédérique, Dreano, Elise, Hatton, Aurélie, Hinzpeter, Alexandre, Pranke, Iwona, Le Clainche-Viala, Laurence, Mayer, Sophie, Corvol, Harriet, Thouvenin, Guillaume, de Miranda, Sandra, Remus, Natascha, Douvry, Benoit, Duthoit, Louise, Perez, Thierry, Le Rouzic, Olivier, Wizla, Nathalie, Bon, Claire, Bui, Stéphanie, Poey, Nora, Stremler, Nathalie, Coltey, Bérengère, Dufeu, Nadine, Lebihan, Jean, Gabsi, Asma, Pouradier, Delphine, Andrejak, Claire, Rames, Cinthia, Dupuy-Grasset, Magali, Languepin, Jeanne, Marguet, Christophe, Pramil, Stéphanie, Arnouat, Baptiste, Fanton, Annlyse, Abely, Michel, Ravoninjatovo, Bruno, Blondé, Aurore, Guillaumot, Anne, Kieffer, Sebastien, Tatopoulos, Aurélie, Nove-Josserand, Raphaële, Ohlmann, Camille, Perrin, Thomas, Reynaud, Quitterie, Llerena, Catherine, Quétant, Sébastien, Valois, Sophie, Dalphin, Marie-Laure, Richaud-Thiriez, Bénédicte, Deneuville, Eric, Chiron, Raphael, Socchi, Floriane, Bihouée, Tiphaine, Mankikian, Julie, Flament, Thomas, Coolen-Allou, Nathalie, Gachelin, Elsa, Périsson, Caroline, Vuillard, Constance, Dupuis, Marion, Alkoussa, Wael, Marchal, Sarah, Leroy, Sylvie, Scalbert, Manuela, Campbell, Karine, Laurans, Muriel, Labbé, Guillaume, Montcouquiol, Sylvie, Priou, Pascaline, de Carli, Paola, Lemonnier, Lydie, Dehillotte, Clémence, Nouvel, Thierry, Burgel, Pierre-Régis, Sermet-Gaudelus, Isabelle, Girodon, Emmanuelle, Durieu, Isabelle, Houdouin, Véronique, Audousset, Camille, Macey, Julie, Grenet, Dominique, Porzio, Michele, Murris-Espin, Marlène, Reix, Philippe, Baravalle, Mélisande, Belleguic, Chantal, Mely, Laurent, Verhille, Juliette, Weiss, Laurence, Reynaud-Gaubert, Martine, Mittaine, Marie, Hamidfar, Rebecca, Ramel, Sophie, Cosson, Laure, Danner-Boucher, Isabelle, Foucaud, Pierre, Roy, Charlotte, Burnet, Espérie, Raynal, Caroline, Audrezet, Marie-Pierre, Da Silva, Jennifer, and Martin, Clémence

Published
2024
Full Text
View/download PDF

2. National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.

Author

Dinh, Aurélien, Bleibtreu, Alexandre, Duran, Clara, Bouchand, Frédérique, Bosch, Alexie, Crozon-Clauzel, Jullien, Roncato-Saberan, Mariam, Matt, Morgan, Boibieux, André, Fanton, Annlyse, Wille, Heidi, Fiaux, Elise, Pilmis, Benoît, Lacoste, Marie, Saint-Genis, Quentin, Thumerelle, Caroline, Pavese, Patricia, Vuotto, Fanny, Senneville, Eric, and Potron, Anaïs

Subjects
WHOLE genome sequencing, RESPIRATORY infections, GRAM-negative bacteria, CITROBACTER freundii, KLEBSIELLA pneumoniae
Abstract

Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France. Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022. Clinical characteristics and outcomes were collected using a standardized questionnaire. The minimum inhibitory concentration (MIC) of antimicrobials, and complete genome sequencing of bacteria were performed when bacterial isolates were available. Results: Ultimately, 21 patients from 15 French hospitals were included in the study. The main indication for MEM-VAB treatment was respiratory tract infections (n = 9). The targeted bacteria included Pseudomonas aeruginosa (n = 12), Klebsiella pneumoniae (n = 3), Enterobacter spp (n = 3), Citrobacter freundii (n = 1), Escherichia coli (n = 1), and Burkholderia multivorans (n = 1). Overall, no significant advantage of vaborbactam over meropenem alone was observed across all strains of P. aeruginosa in terms of in vitro susceptibility. However, MEM-VAB demonstrated a notable impact, compared to carbapenem alone, on the MIC for the two KPC-3-producing K. pneumoniae and B. multivorans. Conclusions: MEM-VAB seems effective as a salvage treatment in compassionate use, but vaborbactam was shown to lack benefits compared to meropenem in treating P. aeruginosa-related infections. Therefore, it is crucial to compare meropenem to MEM-VAB MICs, particularly for P. aeruginosa, before prescribing MEM-VAB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study

Author

Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loic, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, Troussier, Françoise, Person, Christine, Marguet, Christophe, Wizla, Nathalie, Thumerelle, Caroline, Turck, Dominique, Bui, Stéphanie, Fayon, Michael, Duhamel, Alain, Prévotat, Anne, Wallaert, Benoit, Leroy, Sylvie, Bouchara, Jean-Philippe, and Delhaes, Laurence

Published
2017
Full Text
View/download PDF

8. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.

Author

Burgel, Pierre-Régis, Durieu, Isabelle, Chiron, Raphaël, Ramel, Sophie, Danner-Boucher, Isabelle, Prevotat, Anne, Grenet, Dominique, Marguet, Christophe, Reynaud-Gaubert, Martine, Macey, Julie, Mely, Laurent, Fanton, Annlyse, Quetant, Sébastien, Lemonnier, Lydie, Paillasseur, Jean-Louis, Da Silva, Jennifer, Martin, Clémence, and French Cystic Fibrosis Reference Network Study Group

Subjects
CYSTIC fibrosis treatment, CYSTIC fibrosis transmembrane conductance regulator, DRUG efficacy, LUNG transplantation, TREATMENT of respiratory diseases, LAXATIVES, PYRIDINE, QUINOLINE, RESEARCH, COMBINATION drug therapy, INDOLE compounds, PHENOLS, BIOLOGICAL transport, LUNG diseases, HETEROCYCLIC compounds, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, CYSTIC fibrosis, COMPARATIVE studies, LONGITUDINAL method
Abstract

Rationale: Elexacaftor-tezacaftor-ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor-tezacaftor- ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) <40 who initiated elexacaftor-tezacaftor-ivacaftor from December 2019 to August 2020 in France was conducted. Clinical characteristics were collected at initiation and at 1 and 3 months. Safety and effectiveness were evaluated by September 2020. National-level transplantation and mortality figures for 2020 were obtained from the French CF and transplant centers and registries. Measurements and Main Results: Elexacaftor-tezacaftor- ivacaftor was initiated in 245 patients with a median (interquartile range) ppFEV1 = 29 (24-34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis : Results from a French Multicenter Prospective Study

Author

Lafarge, Céline, Pontoire, Bruno, Cayot, Nathalie, Le Bail, Patricia, Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loïc, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, Troussier, Françoise, Person, Christine, Marguet, Christophe, Wizla, Nathalie, Thumerelle, Caroline, Turck, Dominique, Bui, Stéphanie, Fayon, Michael, Duhamel, Alain, Prévotat, Anne, Leroy, Sylvie, Wallaert, Benoit, Bouchara, Jean-Philippe, Delhaes, Laurence, Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de la Recherche Agronomique (INRA), Agroécologie [Dijon], Université de Bourgogne (UB)-Institut National de la Recherche Agronomique (INRA)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, ATOMycA (CRCINA-ÉQUIPE 6), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Laboratoire de Parasitologie et Mycologie (Parasito - Myco - LILLE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Pôle Biologie, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire de Grenoble, Laboratoire de parasitologie-mycologie, CHU Grenoble, CHU Rouen, Normandie Université (NU), Appareil Digestif Environnement Nutrition (ADEN ), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Laboratoire Interactions Muqueuses Agents Transmissibles (LIMA), Université de Bourgogne (UB), Service de pédiatrie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Ressources et de Compétences de la Mucoviscidose [CHU Dijon] (CRCM ), CHU Bordeaux, Ctr Rech Mucoviscidose CRCM Adulte, CHU Bordeaux [Bordeaux], CRCM Adulte [Grenoble], Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie générale et maladies infectieuses, Service de Pneumologie Pédiatrique [Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre Robert Debré, PRES Université Nantes Angers Le Mans (UNAM), Service de pédiatrie médicale et médecine de l'adolescent [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Clinique de Pédiatrie, Hôpital Jeanne de Flandre [Lille]-Université de Lille, Hôpital Jeanne de Flandre [Lille], Pediatrics, CHU Bordeaux, Dept Pediat CRCM, INSERM Ctr Invest Clin CIC5, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Institut d'Informatique et de Mathématiques Appliquées de Grenoble (IMAG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS), Département de Pneumologie, Hôpital A. Calmette, Centre Hospitalier Universitaire de Nice (CHU de Nice), Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Parasitologie et de Mycologie [Lille], Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), French Ministry of Health and Research (PHRC N°2006/1902), the association 'Vaincre la Mucoviscidose' (Defeat Cystic Fibrosis) (MucoFong and Mucofong-ATF N8 2006/351), the Pharmaceutical Division of Pfizer France (Nu 2006/158), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté [COMUE] (UBFC), FLAveur, VIsion et Comportement du consommateur (FLAVIC), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-Etablissement National d'Enseignement Supérieur Agronomique de Dijon (ENESAD), ATIP AVENIR / ATOMycA (CRCINA - Département INCIT - Equipe 6), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Groupe d'Etude des Interactions Hôte-Parasite (GEIHP), Université Grenoble Alpes (UGA), Service de Pédiatrie, Centre de Ressources et de Compétences de la Mucoviscidose [Dijon], Service de Pneumologie et Immuno-Allergologie, Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes (UN)-Université d'Angers (UA), Service de Parasitologie-Mycologie [CHRU LIlle], Institut de Microbiologie [CHRU Lille], Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Pôle de Biologie Pathologie Génétique [CHU Lille], Centre Hospitalier Universitaire [Grenoble] (CHU), université de Bourgogne, PAM, Hôpital Charles Nicolle [Rouen], Université de Bordeaux (UB), CH Dunkerque, Centre de Recherche en Chimie Moléculaire (CRCM), Université Sciences et Technologies - Bordeaux 1 (UB)-Centre National de la Recherche Scientifique (CNRS), Groupe de Recherche sur les Antimicrobiens et les Micro-Organismes (GRAM 1.0), CHU Lille, CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), Hôpital Pasteur [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Procédés Alimentaires et Microbiologiques [Dijon] ( PAM ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Université Bourgogne Franche-Comté ( UBFC ), Unité de recherche sur les Biopolymères, Interactions Assemblages ( BIA ), Institut National de la Recherche Agronomique ( INRA ), FLAveur, VIsion et Comportement du consommateur ( FLAVIC ), Etablissement National d'Enseignement Supérieur Agronomique de Dijon ( ENESAD ) -Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ), ATIP AVENIR / ATOMycA ( CRCINA - Département INCIT - Equipe 6 ), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers ( CRCINA ), Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Groupe d'Etude des Interactions Hôte-Parasite ( GEIHP ), Université d'Angers ( UA ), Laboratoire de Parasitologie et Mycologie ( Parasito - Myco - LILLE ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université Grenoble Alpes - UFR Pharmacie ( UGA UFRP ), Université Grenoble Alpes ( UGA ), Appareil Digestif Environnement Nutrition ( ADEN ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Microbiologie cellulaire et moléculaire et pathogénicité ( MCMP ), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Interactions Muqueuses Agents Transmissibles ( LIMA ), Université de Bourgogne ( UB ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire d'Angers-Centre Robert Debré, Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Université de Bordeaux ( UB ) -CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Bordeaux, Institut d'Informatique et de Mathématiques Appliquées de Grenoble ( IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National Polytechnique de Grenoble ( INPG ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire de Nice ( CHU de Nice ), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] ( CRCTB ), and Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale ( INSERM )

Subjects
Adult, Male, Microbiological Techniques, 0301 basic medicine, medicine.medical_specialty, Filamentous fungi, Adolescent, Veterinary (miscellaneous), Lung mycobiota, 030106 microbiology, Biology, Applied Microbiology and Biotechnology, Microbiology, Cystic fibrosis, Aspergillus fumigatus, Molds, Young Adult, 03 medical and health sciences, Medical microbiology, Exophiala, Mycological examination, medicine, Humans, Prospective Studies, Child, Candida albicans, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Aged, Aged, 80 and over, Aspergillus, Lung Diseases, Fungal, Fungi, Sputum, Scedosporium apiospermum, Middle Aged, biology.organism_classification, [SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Corpus albicans, 030104 developmental biology, Female, France, medicine.symptom, Agronomy and Crop Science
Abstract

IF 1.710; International audience; Fungal respiratory colonization of cystic fibrosis (CF) patients emerges as a new concern; however, the heterogeneity of mycological protocols limits investigations. We first aimed at setting up an efficient standardized protocol for mycological analysis of CF sputa that was assessed during a prospective, multicenter study: “MucoFong” program (PHRC-06/1902). Sputa from 243 CF patients from seven centers in France were collected over a 15-month period and submitted to a standardized protocol based on 6 semi-selective media. After mucolytic pretreatment, sputa were plated in parallel on cycloheximide-enriched (ACT37), erythritol-enriched (ERY37), benomyl dichloran–rose bengal (BENO37) and chromogenic (CAN37) media incubated at 37 °C and on Sabouraud–chloramphenicol (SAB27) and erythritol-enriched (ERY27) media incubated at 20–27 °C. Each plate was checked twice a week during 3 weeks. Fungi were conventionally identified; time for detection of fungal growth was noted for each species. Fungal prevalences and media performances were assessed; an optimal combination of media was determined using the Chi-squared automatic interaction detector method. At least one fungal species was isolated from 81% of sputa. Candida albicans was the most prevalent species (58.8%), followed by Aspergillus fumigatus (35.4%). Cultivation on CAN37, SAB27, ACT37 and ERY27 during 16 days provided an optimal combination, detecting C. albicans, A. fumigatus, Scedosporium apiospermum complex and Exophiala spp. with sensitivities of 96.5, 98.8, 100 and 100%. Combination of these four culture media is recommended to ensure the growth of key fungal pathogens in CF respiratory specimens. The use of such consensual protocol is of major interest for merging results from future epidemiological studies.

Published
2018
Full Text
View/download PDF

10. Chronic Aspergillus fumigatus colonization of respiratory tract in Cystic Fibrosis: Diagnosis, management and antifungal resistance in a French cohort of CF patients

Author

Delhaès, Laurence, Jourdain, A., d'Almeida-Fourquet, M., Fréalle, Emilie, Leroy, Sylvie, Pinel, Claudine, Coltey, Bérengère, Favennec, Loïc, Dominique, S., Vagner, O., Fanton, Annlyse, Bouchara, Jean-Philippe, Person, Christine, Durand-Joly, Isabelle, Loeuille, Guy-André, Domblides, Philippe, Accoceberry, Isabelle, Farce, A., Chavatte, P., Wallaert, Benoit, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Titre abrégé : Chronic Aspergillus fumigatus colonisation of respiratory tract in cystic fibrosis: diagnosis, management and antifungal resistance in a French cohort of cystic fibrosis patients; International audience; Introduction:Cystic fibrosis (CF) is the major genetic inherited diseasein the European Caucasian population, with an average of 1 in 3000 living births in France. Prognostic depend essentially on the lung impairments. While considerable attention therefore has been paid over recent decades to prevent and treat bacterial respiratory infections, we observed emergence of fungi colonization in CF respiratory tract. In particular, Aspergillus fumigatus represents the most common causative agent colonizing the airways of CF patients; it can be responsible for Allergic Bronchopulmonary Aspergillosis (ABPA). Sinceoral corticosteroids and itraconazole represent the mainstay of ABPA treatment, long-term therapy may increase the risk of acquired resistance to azoles that is mainly associated with amino acid substitutions in the CYP51A gene of A. fumigatus.Objective: Because CF patients are chronically exposed to itraconazole, our study aimed to evaluate the prevalence of azole resistance in isolates prospectively collected from CF patients followed-up in seven French hospitals involved in our national prospective study (“MucoFong” study − PHRC1902). To our knowledge, it is the first multicenter studyfocused on azole resistance of A. fumigatus in CF.Methods: A total of 87 isolates of A. fumigatus was collected in 85 patients. The MICs of azole drugs were evaluated for each isolate using the E-test ® strips. Isolates were characterized at the molecular level by targeting ITS, b-tubulin and MAT-A/a genes. The cyp51A gene as well as its promoter was sequenced.Results and Discussion:A majority of isolates (88.1%) were found sensitive to itraconazole (MIC 2 mg/ml), and 2 new mutations were identified and localized within 3-dimensional Cyp51A protein model. To obtain insight into azole resistance of A. fumigatus, the results are analyzed taking into account clinical data, itraconazole exposition, and the potential correlation between the identified CYP5IA mutations and azole resistance is discussed based on the Cyp51A protein homology model.

Published
2011
Full Text
View/download PDF

11. Fungal colonization in Cystic Fibrosis (CF): Epidemiology and antifungal resistance in a French cohort of CF patients – Focused on Aspergillus fumigatus colonization

Author

Delhaès, Laurence, d'Almeida-Fourquet, M., Fréalle, Emilie, Leroy, Stéphane, Pinel, Claudine, Llerana, C., Favennec, Loïc, Dominique, S., Vagner, O., Fanton, Annlyse, Bouchara, Jean-Philippe, Person, Christine, Durand-Joly, Isabelle, Loeuille, Guy-André, Domblides, Philippe, Accoceberry, Isabelle, Farce, A., Chavatte, P., Wallaert, Benoit, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
Exophiala spp, Scedosporium apiospermum, Aspergillus fumigatus, [SDV]Life Sciences [q-bio], antifungal resistance, Cystic fibrosis, Scedosporium prolificans
Abstract

International audience; Introduction: Cystic fibrosis (CF) is the major genetic inherited disease in the European Caucasian population, with an average of 1 in 3000 living births in France. Prognostic dependessentially on the lung impairments. While considerable attention therefore has been paid over recent decades to prevent and treat bacterial respiratory infections, we observed emergence of fungi colonization in CF respiratory tract. In particular, Aspergillus fumigatus represents the most common causative agent colonizing the airways of CF patients; it can be responsible for Allergic Bronchopulmonary Aspergillosis (ABPA). Since oral corticosteroids and itraconazole represent the mainstay of ABPA treatment, long-term therapy may increase the risk of acquired resistance to azoles that is mainly associated with amino acid substitutions in the CYP51A gene of A. fumigatus.Objective: First, we managed to have exhaustive epidemiological data on species of filamentous fungi able to colonize the airway tract of 300 CF patients followed-up in our national prospective study ("MucoFong" study – PHRC1902). Second, CF patients being chronically exposed to azole (especially to itraconazole), our study aimed to evaluate the prevalence of azole resistance in isolates prospectively collected from CF patients followed-up in seven French hospitals involved in our national prospective study. Third, we focused on the most prevalent species: Aspergillus fumigatus, studying the azole resistance at molecular level. To our knowledge, it is the first multicenter study focused on azole resistance of A. fumigatus in CF.Methods:A total of 243 sputa were analyzed using the same protocol in each centre. TheMICs of antifungal drugs were evaluated for each isolate using the E-test ® strips. Focusing on A. fumigatus, a total of 87 isolates was collected in 85 patients. These isolates were characterized at the molecular level by targeting ITS, ß-tubulin and MAT-A/α genes. The CYP51A gene as well as its promoter was sequenced; a 3D Cyp51A protein homology model was built.Results and discussion:300 patients were enrolled in this study. At inclusion time, most of them were adults colonized with A. fumigatus (about 35% of the patients). Scedosporium was isolated in 5%, and Exophiala in about 2%. Regarding antifungal susceptibility, isolates of Scedosporium and Exophiala exhibited antifungal resistance comparable with published data. Regarding A. fumigatus, a majority of isolates (88.1%) were found sensitive to itraconazole (MIC≤ 2μg/ml), and 2 new mutations were identified and localized within 3-dimensional Cyp51A protein model. To obtain insight into azole resistance of A. fumigatus, the results are analyzed taking into account clinical data, itraconazole exposition, and the potential correlation between the identified CYP5IA mutations and azole resistance is discussed based on the Cyp51A protein homology model.

Published
2011

12. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study.

Author

Coron, Noémie, Pihet, Marc, Fréalle, Emilie, Lemeille, Yolande, Pinel, Claudine, Pelloux, Hervé, Gargala, Gilles, Favennec, Loic, Accoceberry, Isabelle, Durand-Joly, Isabelle, Dalle, Frédéric, Huet, Frédéric, Fanton, Annlyse, Boldron, Amale, Loeuille, Guy-André, Domblides, Philippe, Coltey, Bérengère, Pin, Isabelle, Llerena, Catherine, and Troussier, Françoise

Abstract

Fungal respiratory colonization of cystic fibrosis (CF) patients emerges as a new concern; however, the heterogeneity of mycological protocols limits investigations. We first aimed at setting up an efficient standardized protocol for mycological analysis of CF sputa that was assessed during a prospective, multicenter study: 'MucoFong' program (PHRC-06/1902). Sputa from 243 CF patients from seven centers in France were collected over a 15-month period and submitted to a standardized protocol based on 6 semi-selective media. After mucolytic pretreatment, sputa were plated in parallel on cycloheximide-enriched (ACT37), erythritol-enriched (ERY37), benomyl dichloran-rose bengal (BENO37) and chromogenic (CAN37) media incubated at 37 °C and on Sabouraud-chloramphenicol (SAB27) and erythritol-enriched (ERY27) media incubated at 20-27 °C. Each plate was checked twice a week during 3 weeks. Fungi were conventionally identified; time for detection of fungal growth was noted for each species. Fungal prevalences and media performances were assessed; an optimal combination of media was determined using the Chi-squared automatic interaction detector method. At least one fungal species was isolated from 81% of sputa. Candida albicans was the most prevalent species (58.8%), followed by Aspergillus fumigatus (35.4%). Cultivation on CAN37, SAB27, ACT37 and ERY27 during 16 days provided an optimal combination, detecting C. albicans, A. fumigatus, Scedosporium apiospermum complex and Exophiala spp. with sensitivities of 96.5, 98.8, 100 and 100%. Combination of these four culture media is recommended to ensure the growth of key fungal pathogens in CF respiratory specimens. The use of such consensual protocol is of major interest for merging results from future epidemiological studies. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

13. Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.

Author

Campredon A, Battistella E, Martin C, Durieu I, Mely L, Marguet C, Belleguic C, Murris-Espin M, Chiron R, Fanton A, Bui S, Reynaud-Gaubert M, Reix P, Hoang-Thi TN, Vakalopoulou M, Revel MP, Da Silva J, Burgel PR, and Chassagnon G

Abstract

Objectives: Lumacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator known to improve clinical status in people with cystic fibrosis (CF). This study aimed to assess lung structural changes after one year of lumacaftor-ivacaftor treatment, and to use unsupervised machine learning to identify morphological phenotypes of lung disease that are associated with response to lumacaftor-ivacaftor., Methods: Adolescents and adults with CF from the French multicenter real-world prospective observational study evaluating the first year of treatment with lumacaftor-ivacaftor were included if they had pretherapeutic and follow-up chest computed tomography (CT)-scans available. CT scans were visually scored using a modified Bhalla score. A k-mean clustering method was performed based on 120 radiomics features extracted from unenhanced pretherapeutic chest CT scans., Results: A total of 283 patients were included. The Bhalla score significantly decreased after 1 year of lumacaftor-ivacaftor (-1.40±1.53 points compared with pretherapeutic CT; p<0.001). This finding was related to a significant decrease in mucus plugging (-0.35±0.62 points; p<0.001), bronchial wall thickening (-0.24±0.52 points; p<0.001) and parenchymal consolidations (-0.23±0.51 points; p<0.001). Cluster analysis identified 3 morphological clusters. Patients from cluster C were more likely to experience an increase in percent predicted forced expiratory volume in 1 sec (ppFEV 1 ) ≥5 under lumacaftor-ivacaftor than those in the other clusters (54% of responders versus 32% and 33%; p=0.01)., Conclusion: One year treatment with lumacaftor-ivacaftor was associated with a significant visual improvement of bronchial disease on chest CT. Radiomics features on pretherapeutic CT scan may help in predicting lung function response under lumacaftor-ivacaftor., (Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.)

Published
2021
Full Text
View/download PDF

14. Carriage of a Single Strain of Nontoxigenic Corynebacterium diphtheriae bv. Belfanti ( Corynebacterium belfantii ) in Four Patients with Cystic Fibrosis.

Author

Pivot D, Fanton A, Badell-Ocando E, Benouachkou M, Astruc K, Huet F, Amoureux L, Neuwirth C, Criscuolo A, Aho S, Toubiana J, and Brisse S

Subjects
Adult, Anti-Bacterial Agents pharmacology, Corynebacterium diphtheriae drug effects, Corynebacterium diphtheriae genetics, Cystic Fibrosis complications, Cystic Fibrosis epidemiology, Diphtheria epidemiology, Diphtheria microbiology, Female, France, Humans, Male, Whole Genome Sequencing, Asymptomatic Infections, Corynebacterium diphtheriae isolation & purification, Cystic Fibrosis microbiology, Diphtheria transmission
Abstract

Cystic fibrosis (CF) patients are commonly colonized by bacterial pathogens, which can induce persistent lung inflammation and may contribute to clinical deterioration. Colonization of CF patients and cross-transmission by Corynebacterium diphtheriae have not been reported so far. The aim of this article was to investigate the possibility of a cross-transmission of C. diphtheriae biovar Belfanti between four patients of a CF center. C. diphtheriae biovar Belfanti (now formally called C. belfantii ) isolates were collected from four patients in a single CF care center over a period of 6 years and analyzed by microbiological methods and whole-genome sequencing. Epidemiological links among patients were investigated. Ten isolates were collected from 4 patients. Whole-genome sequencing of one isolate from each patient showed that a single strain was shared among them. In addition, one patient was found to have the same strain in two consecutive samplings performed 9 months apart. The strain was nontoxigenic and was susceptible to most antimicrobial agents. Ciprofloxacin resistance was observed in one patient. The idea of transmission of the strain among patients was supported by the occurrence of same-day visits to the CF center. This study demonstrated colonization of CF patients by C. diphtheriae biovar Belfanti ( C. belfantii ), and the data suggest persistence and transmission of a unique strain during at least 6 years in a single CF patient care center., (Copyright © 2019 American Society for Microbiology.)

Published
2019
Full Text
View/download PDF

15. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.

Author

Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, Foucher P, Cottin V, and Bonniaud P

Subjects
Adolescent, Adrenal Cortex Hormones therapeutic use, Adult, Alkylating Agents chemistry, Antineoplastic Agents, Alkylating adverse effects, Child, Preschool, Female, Fibrosis, Humans, Male, Neoplasms complications, Neoplasms drug therapy, Pleura physiopathology, Pneumonia diagnosis, Pneumonia physiopathology, Pulmonary Fibrosis complications, Antineoplastic Agents adverse effects, Lung drug effects, Pulmonary Fibrosis physiopathology
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results